A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia / Yechiel Levkovitz en The Journal of Clinical Psychiatry, Año 2010 - Vol. 71 - No. 2 (Febrero)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 2 (Febrero) . - pp. 138-149 Título : A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia Tipo de documento: texto impreso Autores: Yechiel Levkovitz, Autor ; Shlomo Mendlovich, Autor ; Sharon Riwkes, Autor Fecha de publicación: 2022 Artículo en la página: pp. 138-149 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Cognición, Farmacoterapia, Minociclina, Esquizofrenia, Psicología. Resumen: Current antipsychotics have only a limited effect on 2 core aspects of schizophrenia: negative symptoms and cognitive deficits. Minocycline is a second-generation tetracycline that has a beneficial effect in various neurologic disorders. Recent findings in animal models and human case reports suggest its potential for the treatment of schizophrenia. Link: ./index.php?lvl=notice_display&id=28143 [artículo] A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia [texto impreso] / Yechiel Levkovitz, Autor ; Shlomo Mendlovich, Autor ; Sharon Riwkes, Autor . - 2022 . - pp. 138-149. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 2 (Febrero) . - pp. 138-149 Palabras clave: Antipsicóticos, Cognición, Farmacoterapia, Minociclina, Esquizofrenia, Psicología. Resumen: Current antipsychotics have only a limited effect on 2 core aspects of schizophrenia: negative symptoms and cognitive deficits. Minocycline is a second-generation tetracycline that has a beneficial effect in various neurologic disorders. Recent findings in animal models and human case reports suggest its potential for the treatment of schizophrenia. Link: ./index.php?lvl=notice_display&id=28143

---

1 (1 - 1 / 1)